180 related articles for article (PubMed ID: 28395150)
1. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
[TBL] [Abstract][Full Text] [Related]
2. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
Liu YM; Lee HY; Chen CH; Lee CH; Wang LT; Pan SL; Lai MJ; Yeh TK; Liou JP
Eur J Med Chem; 2015 Jan; 89():320-30. PubMed ID: 25462248
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
4. 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Lee HY; Lee JF; Kumar S; Wu YW; HuangFu WC; Lai MJ; Li YH; Huang HL; Kuo FC; Hsiao CJ; Cheng CC; Yang CR; Liou JP
Eur J Med Chem; 2017 Jan; 125():1268-1278. PubMed ID: 27886544
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
7. Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.
Dung do TM; Dung PT; Oanh DT; Hai PT; Huong le TT; Loi VD; Hahn H; Han BW; Kim J; Han SB; Nam NH
Med Chem; 2015; 11(8):725-35. PubMed ID: 26133355
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
9. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
[TBL] [Abstract][Full Text] [Related]
12. Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Fournier JF; Bhurruth-Alcor Y; Musicki B; Aubert J; Aurelly M; Bouix-Peter C; Bouquet K; Chantalat L; Delorme M; Drean B; Duvert G; Fleury-Bregeot N; Gauthier B; Grisendi K; Harris CS; Hennequin LF; Isabet T; Joly F; Lafitte G; Millois C; Morgentin R; Pascau J; Piwnica D; Rival Y; Soulet C; Thoreau É; Tomas L
Bioorg Med Chem Lett; 2018 Sep; 28(17):2985-2992. PubMed ID: 30122227
[TBL] [Abstract][Full Text] [Related]
13. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH
Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602
[TBL] [Abstract][Full Text] [Related]
14. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
[TBL] [Abstract][Full Text] [Related]
15. Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
Sun JY; Wang JD; Wang X; Liu HC; Zhang MM; Liu YC; Zhang CH; Su Y; Shen YY; Guo YW; Shen AJ; Geng MY
Acta Pharmacol Sin; 2017 Apr; 38(4):551-560. PubMed ID: 28112184
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
18. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Yang Z; Shen M; Tang M; Zhang W; Cui X; Zhang Z; Pei H; Li Y; Hu M; Bai P; Chen L
Eur J Med Chem; 2019 Sep; 178():116-130. PubMed ID: 31177073
[TBL] [Abstract][Full Text] [Related]
20. Indole-3-ethylsulfamoylphenylacrylamides: potent histone deacetylase inhibitors with anti-inflammatory activity.
Mehndiratta S; Hsieh YL; Liu YM; Wang AW; Lee HY; Liang LY; Kumar S; Teng CM; Yang CR; Liou JP
Eur J Med Chem; 2014 Oct; 85():468-79. PubMed ID: 25113875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]